152 related articles for article (PubMed ID: 16550501)
1. Synthesis of enzymatically resistant nociceptin-related peptides containing a carbamic acid residue.
Ligeti M; Bösze S; Csámpai A; Gündüz O; Al-Khrasani M; Rónai AZ; Medzihradszky-Schweiger H; Benyhe S; Borsodi A; Hudecz F; Magyar A
J Pept Sci; 2006 Jul; 12(7):481-90. PubMed ID: 16550501
[TBL] [Abstract][Full Text] [Related]
2. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the binding of [(3)H]nociceptin/orphaninFQ(1-13)NH(2), [(3)H]nociceptin/orphaninFQ(1-17)OH and [(125)I]Tyr(14)nociceptin/orphaninFQ(1-17)OH to recombinant human and native rat cerebrocortical nociceptin/orphanin FQ receptors.
Hashiba E; Lambert DG; Farkas J; Toth G; Smith G
Neurosci Lett; 2002 Aug; 328(1):5-8. PubMed ID: 12123846
[TBL] [Abstract][Full Text] [Related]
4. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.
Kitayama M; Barnes TA; Carra G; McDonald J; Calo G; Guerrini R; Rowbotham DJ; Smith G; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):528-37. PubMed ID: 14598020
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological studies of nociceptin derivatives containing the DTPA chelating group for further labeling with therapeutic radionuclides.
Ligeti M; Gündüz O; Magyar A; Kató E; Rónai AZ; Vita C; Varga I; Hudecz F; Tóth G; Borsodi A; Benyhe S
Peptides; 2005 Jul; 26(7):1159-66. PubMed ID: 15949634
[TBL] [Abstract][Full Text] [Related]
7. [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain.
Berger H; Calo' G; Albrecht E; Guerrini R; Bienert M
J Pharmacol Exp Ther; 2000 Aug; 294(2):428-33. PubMed ID: 10900215
[TBL] [Abstract][Full Text] [Related]
8. Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor.
Guerrini R; Caló G; Bigoni R; Rizzi A; Varani K; Toth G; Gessi S; Hashiba E; Hashimoto Y; Lambert DG; Borea PA; Tomatis R; Salvadori S; Regoli D
J Med Chem; 2000 Jul; 43(15):2805-13. PubMed ID: 10956188
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor.
Guerrini R; Caló G; Bigoni R; Rizzi D; Rizzi A; Zucchini M; Varani K; Hashiba E; Lambert DG; Toth G; Borea PA; Salvadori S; Regoli D
J Med Chem; 2001 Nov; 44(23):3956-64. PubMed ID: 11689082
[TBL] [Abstract][Full Text] [Related]
10. In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13)NH(2) in the mouse and rat colon and the mouse vas deferens.
Menzies JR; Glen T; Davies MR; Paterson SJ; Corbett AD
Eur J Pharmacol; 1999 Dec; 385(2-3):217-23. PubMed ID: 10607879
[TBL] [Abstract][Full Text] [Related]
11. In vitro binding and functional studies of Ac-RYYRIK-ol and its derivatives, novel partial agonists of the nociceptin/orphanin F/Q receptor.
Gunduz O; Sipos F; Spagnolo B; Kocsis L; Magyar A; Orosz G; Borsodi A; Calò G; Benyhe S
Neurosignals; 2006-2007; 15(2):91-101. PubMed ID: 16874009
[TBL] [Abstract][Full Text] [Related]
12. The nociceptin/orphanin FQ receptor ligand acetyl-RYYRIK-amide exhibits antagonistic and agonistic properties.
Berger H; Bigoni R; Albrecht E; Richter RM; Krause E; Bienert M; Calo' G
Peptides; 2000 Jul; 21(7):1131-9. PubMed ID: 10998548
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.
Rizzi A; Spagnolo B; Wainford RD; Fischetti C; Guerrini R; Marzola G; Baldisserotto A; Salvadori S; Regoli D; Kapusta DR; Calo G
Peptides; 2007 Jun; 28(6):1240-51. PubMed ID: 17532097
[TBL] [Abstract][Full Text] [Related]
14. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.
Rizzi A; Rizzi D; Marzola G; Regoli D; Larsen BD; Petersen JS; Calo' G
Br J Pharmacol; 2002 Oct; 137(3):369-74. PubMed ID: 12237257
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells.
Wright KE; McDonald J; Barnes TA; Rowbotham DJ; Guerrini R; Calo' G; Lambert DG
Neurosci Lett; 2003 Aug; 346(3):145-8. PubMed ID: 12853105
[TBL] [Abstract][Full Text] [Related]
17. A structure-activity study of nociceptin-(1-13)-peptide amide. Synthesis of analogues substituted in positions 0, 1, 3, 4 and 10.
Bobrova I; Vlaskovska M; Kasakov L; Surovoy A; Egorova N; Johansson L; Karsnas P; Terenius L
Eur J Med Chem; 2003; 38(7-8):687-94. PubMed ID: 12932899
[TBL] [Abstract][Full Text] [Related]
18. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
Guerrini R; Carra' G; Calo' G; Trapella C; Marzola E; Rizzi D; Regoli D; Salvadori S
J Pept Res; 2004 Jun; 63(6):477-84. PubMed ID: 15175020
[TBL] [Abstract][Full Text] [Related]
19. Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception.
Lohman RJ; Harrison RS; Ruiz-Gómez G; Hoang HN; Shepherd NE; Chow S; Hill TA; Madala PK; Fairlie DP
Vitam Horm; 2015; 97():1-55. PubMed ID: 25677767
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological activity of novel small peptides with aminophosphonates moiety as NOP receptor ligands.
Naydenova ED; Todorov PT; Mateeva PI; Zamfirova RN; Pavlov ND; Todorov SB
Amino Acids; 2010 Nov; 39(5):1537-43. PubMed ID: 20499257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
